Skip to Main Content

Paper Details

Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Clin Cancer Res
30
2020
CD8+, CMV, CMV pp65, CMV+ CD8+ T cells, CMV-T cells, CMV-specific T Cells, CMV-specific T cells, Glioblastoma, PATIENTS, T cells, glioblastoma, glioblastomas, patient, patients, temozolomide, tumor
Author NameAffiliation
John F de GrootThe University of Texas MD Anderson Cancer Center
Rebecca A HarrisonThe University of Texas MD Anderson Cancer Center
Gregory N FullerThe University of Texas MD Anderson Cancer Center
Gregory N FullerThe University of Texas MD Anderson Cancer Center
Jason T HuseThe University of Texas MD Anderson Cancer Center
Ganesh RaoThe University of Texas MD Anderson Cancer Center
Frederick F LangThe University of Texas MD Anderson Cancer Center
Raymond SawayaThe University of Texas MD Anderson Cancer Center
Amy B HeimbergerThe University of Texas MD Anderson Cancer Center
  • 1 - 9

Datasets

Release 1.2